Zobrazeno 1 - 10
of 35
pro vyhledávání: ''
Autor:
Bernard Escudier, Pauline Gaignard, Constance Thibault, Jean-Yves Scoazec, Emeline Colomba, L. Cerbone, Lucia Carril-Ajuria, Aude Flechon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Paillerets, Cecile Vicier, Olivier Caron, Marine Guillaud-Bataille, Guillermo Velasco, Laurence Albiges, Stéphane Richard, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre
Publikováno v:
European journal of cancer (Oxford, England : 1990). 151
Purpose Fumarate hydratase–deficient (FHdef) renal cell carcinoma (RCC) is a rare entity associated with the hereditary leiomyomatosis and RCC syndrome with no standard therapy approved. The aim of this retrospective study was to evaluate the effic
Publikováno v:
European journal of cancer (Oxford, England : 1990). 145
Background Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast cancer (ABC) comparing aromatase inhibitors (AIs) versus the selective estrogen receptor modulator tamoxifen, each individually reported significantly lo
Autor:
Allen Eng Juh Yeoh, Jing J. Eng, Kean H. Chiew, Ah M. Tan, Germaine S.M. Liew, Shawn H. R. Lee, Koon Mian Foo, Cheryl C.C. Neoh, Joyce Ching Mei Lam, Yiong Huak Chan, Zelia Z.L. Seeto, Bernice L. Z. Oh, Zhi W. Chen, Thuan C. Quah
Publikováno v:
European journal of cancer (Oxford, England : 1990). 142
In non-high-risk (non-HR) patients, the Malaysia-Singapore Acute Lymphoblastic Leukaemia 2003 (MS2003) study achieved good outcomes. However, its delayed-intensification (DI) phase, comprising repeated blocks of protocol III (2003-PIII), was toxic an
Autor:
Sophie Postel-Vinay, Capucine Baldini, Jean C. Soria, David Malka, Anas Gazzah, Valérie Boige, Stéphane Champiat, Yolla El-Dakdoukti, Jean M. Michot, Christophe Massard, Antoine Hollebecque, P. Vuagnat, Michel Ducreux, Aurélien Marabelle, Samy Ammari, Andreea Varga, Rastislav Bahleda, Patricia Martin-Romano, Eric Angevin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 137
Background Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy (CT) are the current standard of therapy in several cancer types. Patients (pts) with lung cancer display higher response rates to CT when given after ICIs. Alth
Autor:
Olivier Raffy, Adrien Dixmier, Gérard Zalcman, Clara Fontaine-Delaruelle, Damien Pouessel, Olivier Molinier, Sandrine Hiret, Franck Morin, Patrick-Aldo Renault, Julien Mazieres, Charles Dayen, Patrick Dumont, Catherine Becht, Sylvestre Le Moulec, Eric Pichon, Benjamin Besse, Clarisse Audigier-Valette, Claire Poulet, Fabrice Barlesi, Alexis B. Cortot, Denis Moro-Sibilot, Alexandra Langlais
Publikováno v:
European journal of cancer (Oxford, England : 1990). 131
Purpose Second-line chemotherapy regimens have demonstrated poor benefit after failure of platinum-based chemotherapy in advanced non-squamous non–small-cell lung cancer (nsNSCLC). Methods In this multicentre, open-label phase III trial, patients w
Autor:
Yuji Miyamoto, Martin D. Berger, Chiara Cremolini, Madiha Naseem, Yan Ning, Diana L. Hanna, Marta Schirripa, Ryuma Tokunaga, Francesca Battaglin, Mitsukuni Suenaga, Sebastian Stintzing, Fotios Loupakis, Volker Heinemann, Heinz-Josef Lenz, Alberto Puccini, Shu Cao, Alfredo Falcone, Shivani Soni, Dongyun Yang, Wu Zhang
Publikováno v:
Eur J Cancer
Background Through enhancement of the Wnt signalling pathway, R-spondins are oncogenic drivers in colorectal cancer. Experimental data suggest that the R-spondin/Wnt axis stimulates vascular endothelial growth factor (VEGF)-dependent angiogenesis. We
Autor:
Lionel Geoffrois, David Pérol, Celine Ferlay, Ellen Blanc, Frederic Rolland, Alain Ravaud, Laurence Albiges, Gwenaelle Gravis, Marine Gross-Goupil, Bernard Escudier, Christine Chevreau, Slimane Dermeche, Aude Flechon, Nathalie Rioux-Leclercq, Sylvie Negrier, Helen Boyle
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2020, 129, pp.107-116. ⟨10.1016/j.ejca.2020.02.001⟩
European Journal of Cancer, Elsevier, 2020, 129, pp.107-116. ⟨10.1016/j.ejca.2020.02.001⟩
European Journal of Cancer, 2020, 129, pp.107-116. ⟨10.1016/j.ejca.2020.02.001⟩
European Journal of Cancer, Elsevier, 2020, 129, pp.107-116. ⟨10.1016/j.ejca.2020.02.001⟩
International audience; Introduction: Papillary renal cell carcinoma (PRCC) represents 10%e15% of renal carcinomas. No standard treatments exist for metastatic PRCC (mPRCC) patients. Axitinib is indicated as second-line treatment in metastatic clear
Autor:
Van Cutsem, Eric, Mayer, Robert J, Laurent, Stéphanie, Winkler, Robert, Grávalos, Cristina, Benavides, Manuel, Longo-Munoz, Federico, Portales, Fabienne, Ciardiello, Fortunato, Siena, Salvatore, Yamaguchi, Kensei, Muro, Kei, Denda, Tadamichi, Tsuji, Yasushi, Makris, Lukas, Loehrer, Patrick, Lenz, Heinz-Josef, Ohtsu, Atsushi, RECOURSE Study Group
Publikováno v:
European journal of cancer (Oxford, England : 1990)
Background In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant
Autor:
Éva Remenár, Martin Forster, Judit Kocsis, Magnus T. Dillon, Jonathan Greenberg, Frederic Rolland, Gábor Pajkos, Kevin J. Harrington
Publikováno v:
European journal of cancer (Oxford, England : 1990). 123
Background The fully human monoclonal antibody patritumab blocks HER3 activation, a resistance mechanism to cetuximab, induced by heregulin (HRG). A phase Ib study in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCC
Autor:
Dirk Schadendorf, Gabriella Liszkay, Naoya Yamazaki, Carmen Loquai, Vanna Chiarion Sileni, Helen Gogas, Caroline Dutriaux, Jan Willem B. de Groot, Mario Mandalà, Reinhard Dummer, Michael D Pickard, Caroline Robert, Ashwin Gollerkeri, Ralf Gutzmer, Claus Garbe, Ana Arance, Keith T. Flaherty, Ivana Krajsová, Paolo A. Ascierto
Publikováno v:
European journal of cancer (Oxford, England : 1990). 119
Background Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or pho